Our top pick for
Albireo Pharma, Inc is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 55 staff and has a trailing 12-month revenue of around USD$12 million.
|Latest market close||USD$39.77|
|52-week range||USD$11.26 - USD$43.44|
|50-day moving average||USD$37.6124|
|200-day moving average||USD$31.961|
|Wall St. target price||USD$70.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.228|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||6.91%|
|1 month (2020-12-18)||-2.48%|
|3 months (2020-10-19)||15.91%|
|6 months (2020-07-17)||53.32%|
|1 year (2020-01-17)||59.27%|
|2 years (2019-01-18)||64.68%|
|3 years (2018-01-19)||20.52%|
|5 years (2016-01-19)||15,496.08%|
|Revenue TTM||USD$12 million|
|Gross profit TTM||USD$9.6 million|
|Return on assets TTM||-21.94%|
|Return on equity TTM||-57.66%|
|Market capitalisation||USD$742.9 million|
TTM: trailing 12 months
There are currently 714,791 Albireo Pharma shares held short by investors – that's known as Albireo Pharma's "short interest". This figure is 5.2% up from 679,637 last month.
There are a few different ways that this level of interest in shorting Albireo Pharma shares can be evaluated.
Albireo Pharma's "short interest ratio" (SIR) is the quantity of Albireo Pharma shares currently shorted divided by the average quantity of Albireo Pharma shares traded daily (recently around 173072.88135593). Albireo Pharma's SIR currently stands at 4.13. In other words for every 100,000 Albireo Pharma shares traded daily on the market, roughly 4130 shares are currently held short.
However Albireo Pharma's short interest can also be evaluated against the total number of Albireo Pharma shares, or, against the total number of tradable Albireo Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Albireo Pharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Albireo Pharma shares in existence, roughly 40 shares are currently held short) or 0.0437% of the tradable shares (for every 100,000 tradable Albireo Pharma shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Albireo Pharma.
Find out more about how you can short Albireo Pharma stock.
We're not expecting Albireo Pharma to pay a dividend over the next 12 months.
Albireo Pharma's shares were split on a 1:30 basis on 4 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.
Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $11.26 up to $43.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.6286. This would suggest that Albireo Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.